Now I have all the information needed to write the consolidated review. Let me compose it carefully.

---

## Summary

HG-DCM proposes a framework that transfers knowledge from multiple historical pandemics (Ebola, SARS, Dengue, seasonal flu) to stabilize compartmental-model forecasting for a new outbreak in its data-scarce early stages. A deep learning backbone (ResNet without batch normalization) maps early case trajectories and epidemiological metadata to DELPHI compartmental model parameters, with the key insight that different pandemics share universal human-driven dynamics of spread. The paper constructs a novel multi-pandemic dataset and evaluates on early-stage COVID-19 forecasting across 258 global locations, comparing against DELPHI, an end-to-end CNN, and limited external baselines (GradABM, EiNNs).

## Strengths

- **Novel multi-pandemic dataset**: The paper constructs a dataset spanning Ebola, SARS, Dengue, seasonal influenza, and early COVID-19 with case time-series and country-level metadata (Section 3.1.1). This dataset enables cross-disease transfer and is a concrete community resource.
- **Well-designed ablation isolating historical contribution**: The T-DCM variant (same architecture, no historical data) directly isolates the effect of historical guidance, showing that HG-DCM's median MAE improvements over T-DCM grow with more training data (Table 2). This cleanly supports the claim that historical priors, not architecture, drive the gains.
- **Convincing overshooting reduction**: Figure 4 demonstrates that HG-DCM dramatically reduces catastrophic overshooting predictions compared to DELPHI, with a concrete US example showing DELPHI diverging while HG-DCM tracks the true curve. This directly supports the central claim that historical priors prevent overfitting to sparse early data.
- **Interpretable parameter inference with statistical rigor**: Figure 5 shows HG-DCM produces more constrained, epidemiologically plausible parameter distributions than DELPHI (e.g., lower infection rates, earlier action timing), confirmed by Wilcoxon signed-rank tests (p < 0.05). This demonstrates that the method not only forecasts better but does so for the right reasons.
- **Leak-free augmentation design**: The LDoA mechanism for window-shift augmentation on past pandemics uses retrospective first-wave identification but never applies this during inference on the current pandemic (Section 2.2), preventing look-ahead bias while increasing training diversity.

## Weaknesses

### Fatal

None.

### Major

- **Evaluation restricted to a single target pandemic**: The entire empirical contribution rests on forecasting early-stage COVID-19. The paper's framing promises a general framework for a new emerging pandemic, yet no experiment tests HG-DCM on any other disease as target. The historical set includes biologically diverse diseases (vector-borne Dengue, Ebola, respiratory SARS and flu), so the COVID-19-only evaluation cannot distinguish whether transfer works because of genuinely universal patterns or because COVID-19 overlaps substantially with some training diseases (e.g., flu). The paper's own limitations section (Section 4) does not acknowledge this gap. The "new paradigm" claims in the abstract and introduction are premature without multi-target validation.

- **Mean–median MAE discrepancy is not confronted**: Table 2 reveals that at 4 weeks, HG-DCM's mean MAE (110,452) is nearly 10× worse than CNN's (11,238) and at 2 weeks mean MAE (18,603) is worse than T-DCM's (15,049), yet median MAE favors HG-DCM in both settings. This indicates HG-DCM produces catastrophically large errors on a subset of locations that inflate the mean. The paper never identifies, analyzes, or even acknowledges these failure cases. The claim of "significant improvements" relies entirely on median metrics while ignoring this instability signal. Without this analysis, we cannot assess whether HG-DCM is practically reliable.

- **No validation procedure described**: The paper uses several methodological choices (the β weight balancing historical vs. current loss in Eq. 5, network depth, training schedule) but provides no description of how hyperparameters were selected. Because HG-DCM trains jointly on historical data and the current pandemic's early-stage data, any parameter selection using the same COVID-19 locations constitutes potential train–test leakage. A held-out validation procedure (e.g., subset of locations, or a time-based split) is needed to ensure reported errors are not optimistically biased.

### Minor

- **External baseline comparison is too narrow to support "state-of-the-art" claims**: Table 1 compares against GradABM and EiNNs on only two locations (US, Massachusetts). On those two, HG-DCM loses to EiNNs at 4 weeks (US) and 6 weeks (MA), sometimes by large margins. The paper's language ("consistently lower MAE in most tasks") is technically true but glosses over these reversals. Two locations with mixed results do not substantiate the claim that HG-DCM "consistently and significantly outperforms state-of-the-art methods" (Introduction).

- **β (central hyperparameter) value never reported**: Equation 5 introduces β as the weight controlling how much guidance the model takes from historical vs. current data — arguably the most important hyperparameter in the framework. Its value is never disclosed in the visible paper, making it impossible to assess the sensitivity of results to this choice.

### Trivial

- No statistical significance tests (e.g., Wilcoxon over locations) are reported for the forecasting comparisons in Table 2, which would strengthen the ablation conclusions.

## Nice-to-Haves

- A held-out pandemic experiment (train on all diseases except one, test on the held-out disease) would directly validate the cross-disease transfer claim.
- Profiling the outlier locations where HG-DCM produces large errors (the ones inflating mean MAE) would reveal whether failures are systematic and identifiable.
- Running DELPHI as a baseline across all 258 locations for systematic comparison (rather than relying on the 2-location external comparison) would strengthen the ablation.

## Removed Points

*These points are flagged to be removed; treat them with caution.*

- **"COVID-19 may be included in historical set — leakage concern"**: The paper explicitly states in Section 3.1.2 that COVID-19 is the current pandemic and historical data consists of Ebola, SARS, Dengue, and seasonal flu only. No ambiguity exists. Removed — factually addressed in the paper.
- **"Missing optimizer, learning rate, number of epochs"**: These are routine implementation details that are standard to place in appendices. Per review guidelines, undisclosed hyperparameters of this nature are considered nitpicks. Removed.
- **"GradABM is uniformly worse" as a criticism**: This is factually correct — GradABM loses to HG-DCM in all available comparisons (Table 1, Massachusetts). The asymmetry favors GradABM since it uses detailed mobility data HG-DCM does not. Removed — this is not a weakness of HG-DCM.
- **"The 5× overshooting threshold is arbitrary"**: The paper defines this threshold clearly and uses it consistently across all methods. It is directionally useful and the paper does not claim the specific threshold is canonical. Removed — not a substantive criticism.
- **"Transfer from biologically distinct diseases is untested"**: This is subsumed by the Major weakness about single-target evaluation. Removed as duplication.

## Novel Insights

The paper's most interesting finding is not just that historical data helps, but *how* it helps: HG-DCM shifts the fitted compartmental parameters toward more conservative, epidemiologically plausible values (lower infection rates, earlier action timing, lower death rates — Figure 5). This suggests that the cross-disease transfer is not merely a statistical regularization trick but actually recovers parameter regimes that align with epidemiological expectations, whereas single-disease fitting amplifies early noise into inflated transmission estimates. This parameter-level interpretability is a genuinely valuable property that black-box forecasting models cannot offer.

## Suggestions

- The single most impactful improvement would be a leave-one-disease-out experiment: train on all historical diseases except one, test on that held-out disease. This directly tests the cross-disease transfer claim without requiring a new real pandemic.
- Analyze the locations driving the mean–median MAE discrepancy. Are they small-population locations with noisy data? Are they identifiable ex ante? A scatter plot of per-location error would be informative and would let readers assess practical reliability.
- Report β and a sensitivity analysis showing how performance varies with this weight. This is central to understanding the method's behavior.

## Calibration

Round 1 anchors:
- CpiOUOaqh3 (2.00, Reject): GA-based SEIR parameter fitting. HG-DCM is substantially stronger in methodology and evaluation.
- V83xzYnZ5q (3.00, Reject): TB prediction model. HG-DCM has broader scope and more rigorous ablation.
- w2C7gJqaai (2.33, Reject): Equilibrium state evaluation. HG-DCM has a clearer, better-supported contribution.
- DL7JWbdGr3 / PEMs (4.75, Reject): Most similar paper — pre-trained epidemic time-series models across diseases. HG-DCM has stronger methodology (compartmental integration, better ablation) and a novel dataset. HG-DCM is somewhat stronger.
- Vp2OAxMs2s (5.75, Accept): Hierarchical dynamical systems. Clearly stronger on evaluation breadth, clarity, and methodological depth. HG-DCM is weaker.
- PdaPky8MUn (8.00, Accept): Much stronger paper; different domain. Not comparable.

Round 1 bracket: 4.5–6.0.

Round 2 anchors:
- S8nFZ98pmU (4.75, Reject): Contrastive meta-learning for dynamical systems. HG-DCM has more concrete experiments.
- qq0zZMC4SM (5.00, Reject): Synthetic datasets for spatio-temporal graphs. Similar quality level but different topic.

HG-DCM is clearly stronger than the 4.75-level papers (PEMs, S8nFZ98pmU) due to stronger ablation, novel dataset, and interpretability analysis. It falls short of the 5.75-level Vp2OAxMs2s due to narrower evaluation and unaddressed robustness concerns. Final score: **5.0**.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>